Molecular Partners AG (MOLN.SW)
CHF 4.83
(4.43%)
CHF 4.83
(4.43%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.44 Million CHF | -33.08% |
| 2022 | 3.65 Million CHF | -24.7% |
| 2021 | 4.85 Million CHF | -19.69% |
| 2020 | 6.03 Million CHF | 372.54% |
| 2019 | 1.27 Million CHF | 0.0% |
| 2018 | - CHF | 0.0% |
| 2017 | - CHF | 0.0% |
| 2016 | - CHF | 0.0% |
| 2015 | - CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.83 Million CHF | 0.0% |
| 2024 Q3 | - CHF | 0.0% |
| 2024 Q1 | 2.14 Million CHF | 0.0% |
| 2023 Q3 | 2.74 Million CHF | -9.9% |
| 2023 FY | 2.44 Million CHF | -33.08% |
| 2023 Q1 | 3.35 Million CHF | -8.27% |
| 2023 Q4 | 2.44 Million CHF | -11.03% |
| 2023 Q2 | 3.04 Million CHF | -8.99% |
| 2022 Q2 | 4.25 Million CHF | -6.57% |
| 2022 Q4 | 3.65 Million CHF | -7.59% |
| 2022 Q1 | 4.55 Million CHF | -6.16% |
| 2022 Q3 | 3.95 Million CHF | -7.06% |
| 2022 FY | 3.65 Million CHF | -24.7% |
| 2021 FY | 4.85 Million CHF | -19.69% |
| 2021 Q2 | 5.44 Million CHF | -5.17% |
| 2021 Q4 | 4.85 Million CHF | -5.79% |
| 2021 Q3 | 5.14 Million CHF | -5.45% |
| 2021 Q1 | 5.74 Million CHF | -4.92% |
| 2020 Q2 | 640 Thousand CHF | 0.0% |
| 2020 Q4 | 6.03 Million CHF | 0.0% |
| 2020 Q1 | - CHF | -100.0% |
| 2020 FY | 6.03 Million CHF | 372.54% |
| 2019 Q4 | 1.27 Million CHF | 0.0% |
| 2019 FY | 1.27 Million CHF | 0.0% |
| 2019 Q1 | 1.9 Million CHF | 0.0% |
| 2019 Q2 | 1.9 Million CHF | 0.0% |
| 2019 Q3 | 1.27 Million CHF | -32.84% |
| 2018 Q1 | - CHF | 0.0% |
| 2018 Q2 | - CHF | 0.0% |
| 2018 Q4 | - CHF | 0.0% |
| 2018 Q3 | - CHF | 0.0% |
| 2018 FY | - CHF | 0.0% |
| 2017 FY | - CHF | 0.0% |
| 2017 Q4 | - CHF | 0.0% |
| 2017 Q3 | - CHF | 0.0% |
| 2017 Q2 | - CHF | 0.0% |
| 2017 Q1 | - CHF | 0.0% |
| 2016 FY | - CHF | 0.0% |
| 2016 Q3 | - CHF | 0.0% |
| 2016 Q1 | - CHF | 0.0% |
| 2016 Q4 | - CHF | 0.0% |
| 2016 Q2 | - CHF | 0.0% |
| 2015 Q4 | - CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2015 Q1 | - CHF | 0.0% |
| 2015 FY | - CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q4 | - CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2013 FY | - CHF | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Addex Therapeutics Ltd | 70.38 Thousand CHF | -3372.577% |
| BB Biotech AG | 304.9 Million CHF | 99.198% |
| Basilea Pharmaceutica AG | 95.45 Million CHF | 97.44% |
| Evolva Holding SA | - CHF | -Infinity% |
| Idorsia Ltd | 931 Million CHF | 99.737% |
| Kuros Biosciences AG | 1.56 Million CHF | -56.166% |
| Relief Therapeutics Holding AG | 9000.00 CHF | -27055.556% |
| Santhera Pharmaceuticals Holding AG | 1.47 Million CHF | -65.359% |